Neal Bradsher - Lineage Cell Independent Director
| LCTX Stock | ILA 195.80 32.10 14.09% |
Insider
Neal Bradsher is Independent Director of Lineage Cell Therapeutics, since 2009.
| Age | 53 |
| Tenure | 15 years |
| Phone | 442 287 8990 |
| Web | http://www.lineagecell.com |
Lineage Cell Management Efficiency
The company has return on total asset (ROA) of (13.19) % which means that it has lost $13.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (10.82) %, meaning that it generated substantial loss on money invested by shareholders. Lineage Cell's management efficiency ratios could be used to measure how well Lineage Cell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Avivit Klein | Bank Leumi Le Israel | 54 | |
| Liza Tavori | Ormat Technologies | N/A | |
| Yair Horesh | Azrieli Group | 51 | |
| Maya Grinfeld | ICL Israel Chemicals | N/A | |
| Nitzan Sandor | Israel Discount Bank | N/A | |
| Avraham Ortal | Bank Leumi Le Israel | 56 | |
| Moshe MBA | Mizrahi Tefahot | 52 | |
| Assaf Eldar | Israel Discount Bank | 48 | |
| Aviram Lahav | ICL Israel Chemicals | 64 | |
| Ziv CPA | Bank Leumi Le Israel | 52 | |
| Nirit Zeevi | Azrieli Group | 44 | |
| Anantha Desikan | ICL Israel Chemicals | 51 | |
| Assaf Ginzburg | Ormat Technologies | 48 | |
| Lilach GevaHarel | ICL Israel Chemicals | 43 | |
| Eli Amon | ICL Israel Chemicals | 54 | |
| Adi Shachaf | Mizrahi Tefahot | 49 | |
| Barak Nardi | Israel Discount Bank | 49 | |
| Noam Goldstein | ICL Israel Chemicals | 62 | |
| Eliav David | Bank Leumi Le Israel | N/A | |
| Amir Meshulam | ICL Israel Chemicals | 43 | |
| Shevy Shemer | Mizrahi Tefahot | 59 | |
Management Performance
| Return On Equity | -10.82 | |||
| Return On Asset | -13.19 |
Lineage Cell Therape Leadership Team
Elected by the shareholders, the Lineage Cell's board of directors comprises two types of representatives: Lineage Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lineage. The board's role is to monitor Lineage Cell's management team and ensure that shareholders' interests are well served. Lineage Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lineage Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Mulroy, Independent Director | ||
| Alfred Kingsley, Chairman of the Board, Director | ||
| Brian Culley, Chief Executive Officer, Interim Chief Financial Officer, Director | ||
| Brandi Roberts, Chief Financial Officer, Senior Vice President - Finance | ||
| Gary Hogge, Senior Vice President of Clinical & Medical Affairs | ||
| Alexandra Hernandez, Senior Director of Finance, Controller, Interim Principal Accounting Officer | ||
| Deborah Andrews, Independent Director | ||
| Neal Bradsher, Independent Director | ||
| Angus Russell, Independent Director | ||
| Chase Leavitt, General Counsel and Corporate Secretary | ||
| Don Bailey, Independent Director | ||
| Stephen Farrell, Independent Director |
Lineage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lineage Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.82 | |||
| Return On Asset | -13.19 | |||
| Current Valuation | 1.3 B | |||
| Shares Owned By Insiders | 4.50 % | |||
| Shares Owned By Institutions | 43.81 % | |||
| Revenue | 1.83 M | |||
| Gross Profit | 1.44 M | |||
| EBITDA | (24.77 M) | |||
| Net Income | (11.93 M) | |||
| Cash And Equivalents | 68.75 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Lineage Stock
Lineage Cell financial ratios help investors to determine whether Lineage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lineage with respect to the benefits of owning Lineage Cell security.